"Filgrastim" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant granulocyte colony-stimulating factor (G-CSF) that is used in the treatment and prevention of NEUTROPENIA, preparation and collection of blood progenitor cells, and for use in PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.
| Descriptor ID |
D000069585
|
| MeSH Number(s) |
D12.644.276.374.410.240.350.500 D12.776.395.240.200.500 D12.776.467.374.410.240.350.500 D23.529.374.410.240.350.500
|
| Concept/Terms |
Filgrastim- Filgrastim
- G-CSF Recombinant, Human Methionyl
- G CSF Recombinant, Human Methionyl
- Recombinant-Methionyl Human Granulocyte Colony-Stimulating Factor
- Recombinant Methionyl Human Granulocyte Colony Stimulating Factor
- R-metHuG-CSF
- R metHuG CSF
Zarxio- Zarxio
- Filgrastim-Sandoz
- Filgrastim Sandoz
- FilgrastimSandoz
- Filgrastim-Sndz
- Filgrastim Sndz
|
Below are MeSH descriptors whose meaning is more general than "Filgrastim".
Below are MeSH descriptors whose meaning is more specific than "Filgrastim".
This graph shows the total number of publications written about "Filgrastim" by people in this website by year, and whether "Filgrastim" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Filgrastim" by people in Profiles.
-
FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report. Blood. 2013 Feb 14; 121(7):1083-93.
-
Review and revision of clinical practice of using G-CSF after autologous and allogeneic hematopoietic stem cell transplantation at UCSD. J Oncol Pharm Pract. 2011 Jun; 17(2):85-90.
-
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jun; 15(6):718-23.
-
Myeloid growth factors. J Natl Compr Canc Netw. 2009 Jan; 7(1):64-83.
-
Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer. 2006 Nov; 42(17):2976-81.
-
High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 2006 Jul; 47(7):1290-4.
-
Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol. 2006 Jun; 133(5):533-7.
-
Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2006 Mar; 47(3):481-5.
-
Myeloid growth factors clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005 Jul; 3(4):540-55.
-
Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer. 2004 Jun 15; 100(12):2592-7.